Abstract

Protein phosphatase 2A is a ubiquitously expressed serine/threonine phosphatase that comprises a scaffold, a catalytic, and multiple regulatory subunits and has been shown to be important in the expression of autoimmunity. We considered that a distinct subunit may account for the decreased production of IL-2 in people and mice with systemic autoimmunity. We show that the regulatory subunit PPP2R2D is increased in T cells from people with systemic lupus erythematosus and regulates IL-2 production. Mice lacking PPP2R2D only in T cells produce more IL-2 because the IL-2 gene and genes coding for IL-2–enhancing transcription factors remain open, while the levels of the enhancer phosphorylated CREB are high. Mice with T cell–specific PPP2R2D deficiency display less systemic autoimmunity when exposed to a TLR7 stimulator. While genes related to Treg function do not change in the absence of PPP2R2D, Tregs exhibit high suppressive function in vitro and in vivo. Because the ubiquitous expression of protein phosphatase 2A cannot permit systemic therapeutic manipulation, the identification of regulatory subunits able to control specific T cell functions opens the way for the development of novel, function-specific drugs.

Highlights

  • Systemic lupus erythematosus (SLE) is an autoimmune disease with a complex pathogenesis

  • We have previously shown that phosphatase 2A (PP2A) mRNA, protein, and catalytic activity are increased in T cells from patients with SLE and that PP2AC is responsible for the dephosphorylation of transcriptional enhancer cAMP responsive element binding protein (CREB), which contributes to decreased IL-2 production [14, 15]

  • We present evidence that PPP2R2D, a regulatory subunit of PP2A, negatively regulates IL-2 production in Tconv cells by controlling the chromatin opening of IL-2 and related multiple transcription factors (TFs), which enhance IL-2 transcription

Read more

Summary

Introduction

Systemic lupus erythematosus (SLE) is an autoimmune disease with a complex pathogenesis. The expression of autoimmunity and organ inflammation involves altered production of cytokines by T cells [1,2,3]. Decreased IL-2 production may account for the reported decreased cytotoxic T cell function and the decreased function and numbers of Tregs [2], whereas increased production of IFN-γ and IL-17 may contribute directly to organ inflammation [4, 5]. Treatment with low doses of IL-2 diminishes renal inflammation and the rate of kidney-infiltrating CD4+ T cells in murine lupus nephritis [6]. Low-dose IL-2 in the treatment of autoimmune diseases including SLE, rheumatoid arthritis, and multiple sclerosis is in clinical trials [7]. Tregs have abundant expression of the IL-2 receptor α chain (CD25) but are unable to produce IL-2. Capture of IL-2 by Tregs is critical for their suppressor function and for limiting the activation of T cells [11]

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call